CD44 and Miyoshi myopathy: MM cells have high levels of integrin‐α4β1[4] and CD44,[5] which allow them to enter the BM and stimulate the secretion of IL6,[6] promoting their proliferation and inducing monocyte osteoclast differentiation, ultimately leading to immune escape.[7] Despite advancements in treatment, the median survival of MM patients remains less than eight years, potentially due to the limitations of current therapies that only target MM cells.